



Published in final edited form as:

Nature. 2015 January 22; 517(7535): 455–459. doi:10.1038/nature14098.

A new antibiotic kills pathogens without detectable resistance

Losee L. Ling^{1,*}, Tanja Schneider^{2,3,*}, Aaron J. Peoples¹, Amy L. Spoering¹, Ina Engels^{2,3}, Brian P. Conlon⁴, Anna Mueller^{2,3}, Till F. Schäberle^{3,5}, Dallas E. Hughes¹, Slava Epstein⁶, Michael Jones⁷, Linos Lazarides⁷, Victoria A. Steadman⁷, Douglas R. Cohen¹, Cintia R. Felix¹, K. Ashley Fetterman¹, William P. Millett¹, Anthony G. Nitti¹, Ashley M. Zullo¹, Chao Chen⁴, Kim Lewis⁴

¹NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA.

²Institute of Medical Microbiology, Immunology and Parasitology—Pharmaceutical Microbiology Section, University of Bonn, Bonn 53115, Germany.

³German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany.

⁴Antimicrobial Discovery Center, Northeastern University, Department of Biology, Boston, Massachusetts 02115, USA.

⁵Institute for Pharmaceutical Biology, University of Bonn, Bonn 53115, Germany.

⁶Department of Biology, Northeastern University, Boston, Massachusetts 02115, USA.

⁷Selcia, Ongar, Essex CM5 0GS, UK.

Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99% of all species in external environments, and are an untapped source of new antibiotics. We developed several methods to grow uncultured organisms by cultivation *in situ* or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured

Reprints and permissions information is available at www.nature.com/reprints.

Correspondence and requests for materials should be addressed to K.L. (k.lewis@neu.edu).

Author Contributions K.L. and T.S. designed the study, analysed results, and wrote the paper. L.L.L. designed the study and analysed results. A.J.P. designed the study, performed compound isolation and structure determination and analysed data. B.P.C. designed the study, performed susceptibility experiments and wrote the paper. D.E.H. oversaw preclinical work including designing studies and analysing data. S.E. designed cultivation experiments and analysed data. M.J., L.L. and V.A.S. designed and performed experiments on structure determination and analysed data. I.E. and A.M. designed and performed experiments on mechanism of action. A.L.S., D.R.C., C.R.F., K.A.F., W.P.M., A.G.N., A.M.Z. and C.C. performed experiments on compound production, isolation, susceptibility testing and data analysis. T.F.S. identified the biosynthetic cluster.

*These authors contributed equally to this work.

Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

The biosynthetic gene cluster for teixobactin has been deposited with GenBank under accession number [KP006601](https://www.ncbi.nlm.nih.gov/nuclot/KP006601).

The authors declare competing financial interests: details are available in the online version of the paper. Readers are welcome to comment on the online version of the paper.

Supplementary Information is available in the online version of the paper.

bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of *Staphylococcus aureus* or *Mycobacterium tuberculosis* resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.

Widespread introduction of antibiotics in the 1940s, beginning with penicillin^{1,2} and streptomycin³, transformed medicine, providing effective cures for the most prevalent diseases of the time. Resistance development limits the useful lifespan of antibiotics and results in the requirement for a constant introduction of new compounds^{4,5}. However, antimicrobial drug discovery is uniquely difficult⁶, primarily due to poor penetration of compounds into bacterial cells. Natural products evolved to breach the penetration barriers of target bacteria, and most antibiotics introduced into the clinic were discovered by screening cultivable soil microorganisms. Overmining of this limited resource by the 1960s brought an end to the initial era of antibiotic discovery⁷. Synthetic approaches were unable to replace natural products⁶.

Approximately 99% of all species in external environments are uncultured (do not grow under laboratory conditions), and are a promising source of new antibiotics⁸. We developed several methods to grow uncultured organisms by cultivation in their natural environment^{9,10}, or by using specific growth factors such as iron-chelating siderophores¹¹. Uncultured organisms have recently been reported to produce interesting compounds with new structures/modes of action—lassomycin, an inhibitor of the essential mycobacterial protease ClpP1P2C1 (ref. 12); and diverse secondary metabolites present in a marine sponge *Theonella swinhoei* which are actually made by an uncultured symbiotic *Entotheonella* sp.¹³.

Here we report the discovery of a new cell wall inhibitor, teixobactin, from a screen of uncultured bacteria grown in diffusion chambers *in situ*.

Identification of teixobactin

A multichannel device, the iChip¹⁰, was used to simultaneously isolate and grow uncultured bacteria. A sample of soil is diluted so that approximately one bacterial cell is delivered to a given channel, after which the device is covered with two semi-permeable membranes and placed back in the soil (Extended Data Fig. 1). Diffusion of nutrients and growth factors through the chambers enables growth of uncultured bacteria in their natural environment. The growth recovery by this method approaches 50%, as compared to 1% of cells from soil that will grow on a nutrient Petri dish¹⁰. Once a colony is produced, a substantial number of uncultured isolates are able to grow *in vitro*¹⁴. Extracts from 10,000 isolates obtained by growth in iChips were screened for antimicrobial activity on plates overlaid with *S. aureus*. An extract from a new species of β -proteobacteria provisionally named *Eleftheria terrae* showed good activity. The genome of *E. terrae* was sequenced (Supplementary Discussion). Based on 16S rDNA and *in silico* DNA/DNA hybridization, this organism belongs to a new genus related to *Aquabacteria* (Extended Data Fig. 2, Supplementary Discussion). This group of Gram-negative organisms is not known to produce antibiotics. A partially purified

active fraction contained a compound with a molecular mass of 1,242 Da determined by mass spectrometry, which was not reported in available databases. The compound was isolated and a complete stereochemical assignment has been made based on NMR and advanced Marfey's analysis (Fig. 1, Extended Data Figs 3 and 4 and Supplementary Discussion). This molecule, which we named teixobactin, is an unusual depsipeptide which contains enduracididine, methylphenylalanine, and four D-amino acids. The biosynthetic gene cluster (GenBank accession number [KP006601](#)) was identified using a homology search (Supplementary Discussion). It consists of two large non-ribosomal peptide synthetase (NRPS)-coding genes, which we named *txo1* and *txo2*, respectively (Fig. 1). In accordance with the co-linearity rule, 11 modules are encoded. The *in silico* predicted adenylation domain specificity perfectly matches the amino acid order of teixobactin (Fig. 1), and allowed us to predict the biosynthetic pathway (Extended Data Fig. 5).

Resistance and mechanism of action

Teixobactin had excellent activity against Gram-positive pathogens, including drug-resistant strains (Table 1 and Extended Data Table 1). Potency against most species, including difficult-to-treat enterococci and *M. tuberculosis* was below $1 \mu\text{g ml}^{-1}$. Teixobactin was exceptionally active against *Clostridium difficile* and *Bacillus anthracis* (minimal inhibitory concentration (MIC) of 5 and 20 ng ml^{-1} , respectively). Teixobactin had excellent bactericidal activity against *S. aureus* (Fig. 2a), was superior to vancomycin in killing late exponential phase populations (Fig. 2b), and retained bactericidal activity against intermediate resistance *S. aureus* (VISA) (Extended Data Fig. 6a). Note that frequent clinical failure in patients with *S. aureus* MRSA treated with vancomycin has been linked to the poor bactericidal activity of this compound^{15,16}. Teixobactin was ineffective against most Gram-negative bacteria, but showed good activity against a strain of *E. coli asmB1* with a defective outer membrane permeability barrier (Table 1).

We were unable to obtain mutants of *S. aureus* or *M. tuberculosis* resistant to teixobactin even when plating on media with a low dose ($4 \times \text{MIC}$) of the compound. Serial passage of *S. aureus* in the presence of sub-MIC levels of teixobactin over a period of 27 days failed to produce resistant mutants as well (Fig. 2d, Supplementary Discussion). This usually points to a non-specific mode of action, with accompanying toxicity. However, teixobactin had no toxicity against mammalian NIH/3T3 and HepG2 cells at $100 \mu\text{g ml}^{-1}$ (the highest dose tested). The compound showed no haemolytic activity and did not bind DNA. In order to determine specificity of action of teixobactin, we examined its effect on the rate of label incorporation into the major biosynthetic pathways of *S. aureus*. Teixobactin strongly inhibited synthesis of peptidoglycan, but had virtually no effect on label incorporation into DNA, RNA and protein (Fig. 3a). This suggested that teixobactin is a new peptidoglycan synthesis inhibitor.

Resistance has not developed to this compound, suggesting that the target is not a protein. The essential lack of resistance development through mutations has been described for vancomycin which binds lipid II, the precursor of peptidoglycan. We reasoned that teixobactin could be acting against the same target. Treatment of whole cells of *S. aureus* with teixobactin ($1\text{--}5 \times \text{MIC}$) resulted in significant accumulation of the soluble cell wall

precursor undecaprenyl-*N*-acetylmuramic acid-pentapeptide (UDP-MurNAc-pentapeptide), similar to the vancomycin-treated control cells (Fig. 3b), showing that one of the membrane-associated steps of peptidoglycan biosynthesis is blocked. Teixobactin inhibited peptidoglycan biosynthesis reactions *in vitro* in a dose-dependent manner with either lipid I, lipid II or undecaprenyl-pyrophosphate (Fig. 3c) as a substrate. Quantitative analysis of the MurG-, FemX-, and PBP2-catalysed reactions using radiolabelled substrates, showed an almost complete inhibition at a twofold molar excess of teixobactin with respect to the lipid substrate (Fig. 3c). The addition of purified lipid II prevented teixobactin from inhibiting growth of *S. aureus* (Extended Data Table 2). These experiments showed that teixobactin specifically interacts with the peptidoglycan precursor, rather than interfering with the activity of one of the enzymes. In order to evaluate the minimal motif required for high affinity binding of teixobactin, the direct interaction with several undecaprenyl-coupled cell envelope precursors was investigated. Purified precursors were incubated with teixobactin at different molar ratios, followed by extraction and subsequent thin-layer chromatography analysis (Fig. 3d). In agreement with the results obtained from the *in vitro* experiments, lipid I and lipid II were fully trapped in a stable complex that prevented extraction of the lipid from the reaction mixture in the presence of a twofold molar excess of the antibiotic, leading to the formation of a 2:1 stoichiometric complex. Teixobactin was active against vancomycin-resistant enterococci that have modified lipid II (lipid II-D-Ala-D-Lac or lipid II-D-Ala-D-Ser instead of lipid II-d-Ala-D-Ala)^{17–19}. This suggested that, unlike vancomycin, teixobactin is able to bind to these modified forms of lipid II. Indeed, teixobactin bound to lipid II-D-Ala-D-Lac and lipid II-D-Ala-D-Ser (Extended Data Fig. 6b). Moreover, teixobactin efficiently bound to the wall teichoic acid (WTA) precursor undecaprenyl-PP-GlcNAc (lipid III). Although WTA is not essential *per se*, inhibition of late membrane-bound WTA biosynthesis steps is lethal due to accumulation of toxic intermediates²⁰. Furthermore, teichoic acids anchor autolysins, preventing uncontrolled hydrolysis of peptidoglycan²¹. Inhibition of teichoic acid synthesis by teixobactin would help liberate autolysins, contributing to the excellent lytic and killing activity of this antibiotic. Teixobactin was also able to bind undecaprenyl-pyrophosphate, but not undecaprenyl-phosphate (Fig. 3d and Extended Data Table 2). Although teixobactin efficiently binds lipid I *in vitro*, this is probably less significant for antimicrobial activity, as this is the intracellular form of the precursor, unlike surface-exposed lipid II and the undecaprenyl-PP-GlcNAc WTA precursors (Fig. 3e and Extended Data Fig. 7). Binding to the target primarily relies on the interaction of the antibiotic with the pyrophosphate moiety, and the first sugar moiety attached to the lipid carrier, as higher concentrations of teixobactin were required to completely inhibit the YbjG-catalysed monophosphorylation of undecaprenyl-pyrophosphate, involved in the recycling process of the essential lipid carrier (Fig. 3c and Extended Data Fig. 7). Corroborating this result, a tenfold higher concentration of undecaprenyl-pyrophosphate was required to antagonize the antimicrobial activity of teixobactin compared to lipid II (Extended Data Table 2). The exact nature of this first sugar is therefore not important, explaining why teixobactin is active against *M. tuberculosis*, where it probably binds to decaprenyl-coupled lipid intermediates of peptidoglycan and arabinogalactan. Teixobactin is also likely to bind to prenyl-PP-sugar intermediates of capsular polysaccharide biosynthesis which is important for virulence in staphylococci²² and whose inhibition of biosynthesis is lethal in streptococci²³.

In vivo efficacy

Given the attractive mode of action of this compound, we investigated its potential as a therapeutic. The compound retained its potency in the presence of serum, was stable, and had good microsomal stability and low toxicity (Supplementary Discussion). The pharmacokinetic parameters determined after i.v. injection of a single 20 mg per kg dose in mice were favourable, as the level of compound in serum was maintained above the MIC for 4 h (Extended Data Fig. 8). An animal efficacy study was then performed in a mouse septicemia model. Mice were infected intraperitoneally with methicillin-resistant *S. aureus* (MRSA) at a dose that leads to 90% of death. One hour post-infection, teixobactin was introduced i.v. at single doses ranging from 1 to 20 mg per kg. All treated animals survived (Fig. 4a), and in a subsequent experiment the PD₅₀ (protective dose at which half of the animals survive) was determined to be 0.2 mg per kg, which compares favourably to the 2.75 mg per kg PD₅₀ of vancomycin, the main antibiotic used to treat MRSA. Teixobactin was then tested in a thigh model of infection with *S. aureus*, and showed good efficacy as well (Fig. 4b). Teixobactin was also highly efficacious in mice infected with *Streptococcus pneumoniae*, causing a 6 log₁₀ reduction of c.f.u. in lungs (Fig. 4c).

Discussion

This study, as well as previous work^{12,13,24} suggests that new organisms such as uncultured bacteria are likely to harbour new antimicrobials²⁵. This is consistent with resistance mechanisms in soil bacteria being stratified by phylogeny, with horizontal transmission limited²⁶ (as compared to pathogens) and the pattern of antibiotic production correlating with resistance. Exploiting uncultured bacteria is likely to revive the Waxman platform of natural product drug discovery⁷. Teixobactin is a promising therapeutic candidate; it is effective against drug-resistant pathogens in a number of animal models of infection. Binding of teixobactin to WTA precursor contributes to efficient lysis and killing, due to digestion of the cell wall by liberated autolysins. This is akin to the action of another natural product with excellent killing ability, acyldepsipeptide, which converts the ClpP protease into a non-specific hydrolase that digests the cell²⁷. These examples show that natural products evolved to exploit the inherent weaknesses of bacteria²⁸, and additional compounds that subvert important enzymes into killing devices are likely to be discovered. Teixobactin binds to multiple targets, none of which is a protein (Fig. 3e and Extended Data Fig. 7). Polyprenyl-coupled cell envelope precursors, such as lipid II, are readily accessible on the outside of Gram-positive bacteria and represent an ‘Achilles heel’ for antibiotic attack²⁸. The target of teixobactin, the pyrophosphate-sugar moiety of these molecules, is highly conserved among eubacteria. The producer is a Gram-negative bacterium, and its outer membrane will protect it from re-entry of the compound (Fig. 3e and Extended Data Fig. 7). This suggests that the producer does not employ an alternative pathway for cell wall synthesis that would protect it from teixobactin, and which other bacteria could borrow. Resistance could eventually emerge from horizontal transmission of a resistance mechanism from some soil bacterium, and given the highly conserved teixobactin binding motif, this would likely take the form of an antibiotic modifying enzyme. However, although determinants coding for enzymes attacking frequently found antibiotics such as β -lactams or aminoglycosides are common, they are unknown for the rare vancomycin. The recently

discovered teixobactin is even less common than vancomycin. After its introduction into the clinic, it took 30 years for vancomycin resistance to appear²⁹. The lipid II modification pathway resulting in vancomycin resistance probably originated in the producer of vancomycin, *Amycolatopsis orientalis*¹⁹. It will probably take even longer for resistance to the better-protected teixobactin to emerge. Teixobactin is the first member of a new class of lipid II binding antibiotics, structurally distinct from glycopeptides, lantibiotics^{30,31}, and defensins³². The properties of teixobactin suggest that it evolved to minimize resistance development by target microorganisms. It is likely that additional natural compounds with similarly low susceptibility to resistance are present in nature and are waiting to be discovered.

METHODS

Isolation and cultivation of producing strains.

A sample of 1 g of soil sample collected from a grassy field in Maine was agitated vigorously in 10 ml of deionized H₂O for 10 min. After letting the soil particulates settle for 10 min, the supernatant was diluted in molten SMS media (0.125 g casein, 0.1 g potato starch, 1 g casamino acids, 20 g bacto-agar in 1 litre of water) to achieve an average concentration of one cell per 20 µl of medium. Then 20 µl aliquots were then dispensed into the wells of an iChip. The iChip was placed in direct contact with the soil. After one month of incubation, the iChips were disassembled and individual colonies were streaked onto SMS agar to test for the ability to propagate outside the iChip and for colony purification.

Extract preparation and screening for activity.

Isolates that grew well outside the iChip were cultured in seed broth (15 g glucose, 10 g malt extract, 10 g soluble starch, 2.5 g yeast extract, 5 g casamino acids, and 0.2 g CaCl₂•2H₂O per 1 litre of deionized H₂O, pH 7.0) to increase biomass, followed by 1:20 dilution into 4 different fermentation broths. After 11 days of agitation at 29 °C, the fermentations were dried and resuspended in an equal volume of 100% DMSO. Then 5 µl of extracts were spotted onto a lawn of growing *S. aureus* NCTC8325–4 cells in Mueller-Hinton agar (MHA) plates. After 20 h of incubation at 37 °C, visible clearing zones indicated antibacterial activity. The extract from this isolate, which was provisionally named *Eleftheria terrae* sp., produced a large clearing zone. Although *E. terrae* sp. produced antibacterial activity under several growth conditions, the best activity (that is, largest clearing zone) was seen with R4 fermentation broth (10 g glucose, 1 g yeast extract, 0.1 g casamino acids, 3 g proline, 10 g MgCl₂•6H₂O, 4 g CaCl₂•2H₂O, 0.2 g K₂SO₄, 5.6 g TES free acid (2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl]amino]ethanesulfonic acid) per 1 litre of deionized H₂O, pH 7).

Sequencing of the strain.

Genomic DNA of *E. terrae* was isolated. Sequencing was performed at the Tufts University Core Facility (Boston, MA). A paired-end library with an insert size of approximately 800 bases was generated and sequenced using Illumina technology. The read length was 251 bases per read.

Strain identification.

A suspension of cells was disrupted by vigorous agitation with glass beads (106 nm or smaller) and the supernatant used as template to amplify the 16S rRNA gene, using GoTaq Green Master Mix (Promega M7122), and the universal primers E8F and U1510R³³. The thermocycler parameters included 30 cycles of 95 °C for 30 s, 45 °C for 30 s and 72 °C for 105 s. The amplified DNA fragment was sequenced by MacroGen USA (Cambridge, MA), and the sequence compared by BLAST to cultured isolates in the Ribosomal Database Project.

The assembled genome for *E. terrae* was submitted to the RAST genome annotation server at (<http://rast.nmpdr.org/>)³⁴ which produced a list of closest relatives with published genomes. These are *Alicyclophilus denitrificans*, *Leptothrix cholodnii*, *Methylobium petroleiphilum*, and *Rubrivivax gelatinosus*, and their genomes were downloaded from the NCBI ftp site (ftp://ftp.ncbi.nih.gov/genomes/ASSEMBLY_BACTERIA/). DNA–DNA hybridization (DDH) values of these genomes to *E. terrae* were then predicted by the Genome-to-Genome Distance calculator 2.0, formula 2, (<http://ggdc.dsmz.de/>)^{35–37}. Note that *M. petroleiphilum* and *R. gelatinosus* are present on the phylogeny tree of *E. terrae* (Extended Data Fig. 2).

Biosynthetic gene cluster identification.

By screening the draft genome of *E. terrae*, obtained by Illumina sequencing, many gene fragments putatively belonging to NRPS coding genes were identified. The assembly was manually edited and gap closure PCRs were performed. Sanger sequencing of the resulting fragments allowed the closure of the gene locus corresponding to the teixobactin biosynthetic gene cluster. The specificity of the adenylation domains was determined using the online tool NRPSpredictor2 (ref. 38).

Strain fermentation and purification of teixobactin.

Homogenized colonies were first grown with agitation in seed broth. After 4 days at 28 °C, the culture was diluted 5% (v/v) into the R4 fermentation media, and production monitored with analytical HPLC. For scale-up isolation and purification of teixobactin, 40 litres of cells were grown in a Sartorius Biostat Cultibag STR 50/200 Bioreactor for about 7 days. The culture was centrifuged and the pellet extracted with 10 litres of 50% aqueous acetonitrile and the suspension again centrifuged for 30 min. The acetonitrile was removed from the supernatant by rotary evaporation under reduced pressure until only water remained. The mixture was then extracted twice with 5 litres of n-BuOH. The organic layer was transferred to a round bottom flask and the n-BuOH removed by rotary evaporation under reduced pressure. The resulting yellow solid was dissolved in DMSO and subjected to preparatory HPLC (SP: C18, MP: H₂O/MeCN/0.1% TFA). The fractions containing teixobactin were then pooled and the acetonitrile removed by rotary evaporation under reduced pressure. The remaining aqueous mixture was then lyophilized to leave a white powder (trifluoroacetate salt). Teixobactin was then converted to a hydrochloride salt, and endotoxin removed as follows. 100 mg of teixobactin (TFA salt) was dissolved in 100 ml of H₂O and 5 g of Dowex (1 × 4 Cl[−] form) was added and the mixture incubated for 20 min with occasional shaking. A 10 g Dowex (1×4 Cl[−] form) column was prepared and the mixture was then poured onto

the prepared column and the solution was allowed to elute slowly. This solution was then poured over a fresh 10 g Dowex (1×4 Cl⁻ form) column and the resulting solution filtered through a Pall 3K Molecular Weight Centrifugal filter. The clear solution was then lyophilized to leave a white powder.

Minimum inhibitory concentration (MIC).

MIC was determined by broth micro-dilution according to CLSI guidelines. The test medium for most species was cation-adjusted Mueller-Hinton broth (MHB). The same test medium was supplemented with 3% lysed horse blood (Cleveland Scientific, Bath, OH) for growing Streptococci. *Haemophilus* Test Medium was used for *H. influenzae* (Teknova, Hollister, CA), Middlebrook 7H9 broth (Difco) was used for mycobacteria, Schaedler anaerobe broth (Oxoid) was used for *C. difficile*, and fetal bovine serum (ATCC) was added to MHB (1:10) to test the effect of serum. All test media were supplemented with 0.002% polysorbate 80 to prevent drug binding to plastic surfaces³⁹, and cell concentration was adjusted to approximately 5×10^5 cells per ml. After 20 h of incubation at 37 °C (2 days for *M. smegmatis*, and 7 days for *M. tuberculosis*), the MIC was defined as the lowest concentration of antibiotic with no visible growth. Expanded panel antibacterial spectrum of teixobactin was tested at Micromyx, Kalamazoo, MI, in broth assays. Experiments were performed with biological replicates.

Minimum bactericidal concentration (MBC).

S. aureus NCTC8325–4 cells from the wells from an MIC microbroth plate that had been incubated for 20 h at 37 °C were pelleted. An aliquot of the initial inoculum for the MIC plate was similarly processed. The cells were resuspended in fresh media, plated onto MHA, and the colonies enumerated after incubating for 24 h at 37 °C. The MBC is defined as the first drug dilution which resulted in a 99.9% decrease from the initial bacterial titre of the starting inoculum, and was determined to be $2 \times \text{MIC}$ for teixobactin. Experiments were performed with biological replicates.

Time-dependent killing.

An overnight culture of cells (*S. aureus* HG003; vancomycin intermediate *S. aureus* SA1287) was diluted 1:10,000 in MHB and incubated at 37 °C with aeration at 225 r.p.m. for 2 h (early exponential) or 5 h (late exponential). Bacteria were then challenged with antibiotics at $10 \times \text{MIC}$ (a desirable concentration at the site of infection), oxacillin ($1.5 \mu\text{g ml}^{-1}$), vancomycin ($10 \mu\text{g ml}^{-1}$) or teixobactin ($3 \mu\text{g ml}^{-1}$) in culture tubes at 37 °C and 225 r.p.m. At intervals, 100 μl aliquots were removed, centrifuged at $10,000g$ for 1 min and resuspended in 100 μl of sterile phosphate buffered saline (PBS). Tenfold serially diluted suspensions were plated on MHA plates and incubated at 37 °C overnight. Colonies were counted and c.f.u. per ml was calculated. For analysis of lysis, 12.5 ml of culture at $A_{600\text{nm}}$ (OD₆₀₀) of 1.0 was treated with $10 \times \text{MIC}$ of antibiotics for 24 h, after which, 2 ml of each culture was added to glass test tubes and photographed. Experiments were performed with biological replicates.

Resistance studies.

For single step resistance, *S. aureus* NCTC8325–4 at 10^{10} c.f.u. were plated onto MHA containing 2 \times , 4 \times , and 10 \times MIC of teixobactin⁴⁰. After 48 h of incubation at 37 °C, no resistant colonies were detected, giving the calculated frequency of resistance to teixobactin of $< 10^{-10}$. For *M. tuberculosis*, cells were cultured in 7H9 medium and plated at 10^9 cells per ml on 10 plates and incubated for 3 weeks at 37 °C for colony counts. No colonies were detected.

For resistance development by sequential passaging^{40,41}, *S. aureus* ATCC 29213 cells at exponential phase were diluted to an $A_{600\text{nm}}$ (OD₆₀₀) of 0.01 in 1 ml of MHB supplemented with 0.002% polysorbate 80 containing teixobactin or ofloxacin. Cells were incubated at 37 °C with agitation, and passaged at 24 h intervals in the presence of teixobactin or ofloxacin at subinhibitory concentration (see Supplementary Discussion for details). The MIC was determined by broth microdilution. Experiments were performed with biological replicates.

Mammalian cytotoxicity.

The CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) was used to determine the cytotoxicity of teixobactin. Exponentially growing NIH/3T3 mouse embryonic fibroblast (ATCC CRL-1658, in Dulbecco's Modified Eagle's medium supplemented with 10% bovine calf serum), and HepG2 cells (ATCC HB-8065, in Dulbecco's Modified Eagle's medium supplemented with 10% fetal calf serum) were seeded into a 96-well flat bottom plate, and incubated at 37 °C. After 24 h, the medium was replaced with fresh medium containing test compounds (0.5 μ l of a twofold serial dilution in DMSO to 99.5 μ l of media). After 48 h of incubation at 37 °C, reporter solution was added to the cells and after 2 h, the $A_{490\text{nm}}$ (OD₄₉₀) was measured using a Spectramax Plus Spectrophotometer. Experiments were performed with biological replicates.

Haemolytic activity.

Fresh human red blood cells were washed with PBS until the upper phase was clear after centrifugation. The pellet was resuspended to an $A_{600\text{nm}}$ (OD₆₀₀) of 24 in PBS, and added to the wells of a 96-well U-bottom plate. Teixobactin was serially diluted twofold in water and added to the wells resulting in a final concentration ranging from 0.003 to 200 μ g ml⁻¹. After one hour at 37 °C, cells were centrifuged at 1,000g. The supernatant was diluted and $A_{450\text{nm}}$ (OD₄₅₀) measured using a Spectramax Plus Spectrophotometer. Experiments were performed with biological replicates.

Macromolecular synthesis.

S. aureus NCTC8325–4 cells were cultured in minimal medium (0.02 M HEPES, 0.002 M MgSO₄, 0.0001 M CaCl₂, 0.4% succinic acid, 0.043 M NaCl₂, 0.5% (NH₄)₂ SO₄) supplemented with 5% tryptic soy broth (TSB). Cells were pelleted and resuspended into fresh minimal medium supplemented with 5% TSB containing test compounds and radioactive precursors to a density of 10^8 cells per ml. The radioactive precursors were glucosamine hydrochloride, D-[6-³H(N)] (1 mCi ml⁻¹), leucine, L-[3,4,5-³H(N)] (1 mCi ml⁻¹), uridine, [5-³H] (1 mCi ml⁻¹), or thymidine, [methyl-³H] (0.25 mCi ml⁻¹) to measure cell wall, protein, RNA, and DNA synthesis, respectively. After 20 min of incubation at 37

°C, aliquots were removed, added to ice cold 25% trichloroacetic acid (TCA), and filtered using Multiscreen Filter plates (Millipore Cat. MSDVN6B50). The filters were washed twice with ice cold 25% TCA, twice with ice-cold water, dried and counted with scintillation fluid using Perkin Elmer MicroBeta TriLux Microplate Scintillation and Luminescence counter. Experiments were performed with biological replicates.

Intracellular accumulation of UDP-N-acetyl-muramic acid pentapeptide.

Analysis of the cytoplasmic peptidoglycan nucleotide precursor pool was examined using *S. aureus* ATCC 29213 grown in 25 ml MHB. Cells were grown to an $A_{600\text{nm}}$ (OD₆₀₀) of 0.6 and incubated with 130 $\mu\text{g ml}^{-1}$ of chloramphenicol for 15 min. Teixobactin was added at 1, 2.5 and 5 \times MIC and incubated for another 60 min. Vancomycin (VAN; 10 \times MIC), known to form a complex with lipid II, was used as positive control. Cells were collected and extracted with boiling water. The cell extract was then centrifuged and the supernatant lyophilized⁴². UDP-linked cell wall precursors were analysed by RP18-HPLC⁴³ and confirmed by MALDI-ToF⁴⁴ mass spectrometry. Experiments were performed with biological replicates.

Cloning, overexpression and purification of *S. aureus* UppS and YbjG as His₆-tag fusions.

S. aureus N315 *uppS* (SA1103) and *ybjB* (SA0415) were amplified using forward and reverse primers *uppS*_FW-59-TCGGAGGAAAGCATATGTTTAAAAAGC-39, *uppS*_RV-59-ATACTCTCGAGCTCCTCACTC-39, SA0415_FW-59-GCGCGGGATCCATGATAGATAAAAAATTAACATCAC-39 and SA0415_RV-59-GCGCGCTCGAGAACGCGTTGTCGTCGATGAT-39, respectively and cloned into a modified pET20 vector⁴⁴ using restriction enzymes NdeI (*uppS*) or BamHI (*ybjG*) and XhoI, to generate C-terminal His₆-fusion proteins. Recombinant UppS-His₆ enzyme was overexpressed and purified as described for MurG³². For overexpression and purification of YbjG-His₆ *E. coli* BL21(DE3) C43 cells transformed with the appropriate recombinant plasmid were grown in 2YT-medium (50 $\mu\text{g ml}^{-1}$ ampicillin) at 25 °C. At an $A_{600\text{nm}}$ (OD₆₀₀) of 0.6, IPTG was added at a concentration of 1 mM to induce expression of the recombinant proteins. After 16 h, cells were harvested and resuspended in buffer A (25 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM β -mercaptoethanol, 30% glycerol, and 1 mM MgCl₂). 2 mg ml⁻¹ lysozyme, 75 $\mu\text{g ml}^{-1}$ DNase and 75 $\mu\text{g ml}^{-1}$ RNase were added; cells were incubated for 1 h on ice, sonicated and the resulting suspension was centrifuged (20,000g, 30 min, 4 °C). Pelleted bacterial membranes were washed three times to remove remaining cytoplasmic content. Membrane proteins were solubilized in two successive steps with buffer A containing 17.6 mM *n*-dodecyl- β -D-maltoside (DDM). Solubilized proteins were separated from cell debris by centrifugation (20,000g, 30 min, 4 °C) and the supernatant containing recombinant proteins was mixed with Talon-agarose (Clontech) and purification was performed⁴². Purity was controlled by SDS-PAGE and protein concentration was determined using Bradford protein assay (Biorad).

***In vitro* peptidoglycan synthesis reactions.**

In vitro peptidoglycan biosynthesis reactions were performed as described using purified enzymes and substrates^{32,45}. The MurG activity assay was performed in a final volume of 30 μl containing 2.5 nmol purified lipid I, 25 nmol UDP-N-acetyl glucosamine (UDP-GlcNAc)

in 200 mM Tris-HCl, 5.7 mM MgCl₂, pH 7.5, and 0.8% Triton X-100 in the presence of 0.45 µg of purified, recombinant MurG-His₆ enzyme. Reaction mixtures were incubated for 60 min at 30 °C. For quantitative analysis 0.5 nmol of [¹⁴C]-UDP-GlcNAc (9.25 GBq mmol⁻¹; ARC) was added to the reaction mixtures. The assay for synthesis of lipid II-Gly₁ catalysed by FemX was performed as described previously without any modifications^{32,45}. Enzymatic activity of *S. aureus* PBP2 was determined by incubating 2 nmol [¹⁴C]-lipid II in 100 mM MES, 10 mM MgCl₂, pH 5.5 in a total volume of 50 µl. The reaction was initiated by the addition of 5 mg PBP2-His₆ and incubated for 2.5 h at 30 °C. Monophosphorylation of C₅₅-PP was carried out using purified *S. aureus* YbjG-His₆ enzyme as described previously for *E. coli* pyrophosphatase⁴⁶, with modifications. 0.5 nmol [¹⁴C]-C₅₅-PP (1.017 kBq) was incubated with 0.6 µg YbjG-His₆ in 20 mM Tris/HCl, pH 7.5, 60 mM NaCl, 0.8% Triton X-100 for 10 min at 30 °C.

In all *in vitro* assays teixobactin was added in molar ratios ranging from 0.25 to 8 with respect to the amount of [¹⁴C]-C₅₅-PP, lipid I or lipid II and [¹⁴C]-lipid II, respectively. Synthesized lipid intermediates were extracted from the reaction mixtures with *n*-butanol/pyridine acetate, pH 4.2 (2:1; vol/vol) after supplementing the reaction mixture with 1 M NaCl and analysed by thin-layer chromatography (TLC). Quantification was carried out using phosphoimaging (Storm imaging system, GE Healthcare) as described^{32,45}. Experiments were performed with biological replicates.

Synthesis and purification of lipid intermediates.

Large scale synthesis and purification of the peptidoglycan precursors lipid I and II was performed⁴⁵. Radio-labelled lipid II was synthesized using [¹⁴C]-UDP-GlcNAc (9.25 GBq mmol⁻¹; ARC) as substrate. For synthesis of the lipid II variant with a terminal D-Lac residue, UDP-MurNAc-depsipeptide (Ala-Glu-Lys-Ala-Lac) was purified from *Lactobacillus casei* ATCC393. Briefly, *L. casei* was grown in MRS broth to an A_{600nm} (OD₆₀₀) of 0.6 and incubated with 65 µg ml⁻¹ of chloramphenicol for 15 min. Intracellular accumulation was achieved by incubation with Bacitracin (10 × MIC, 40 µg ml⁻¹) in the presence of 1.25 mM zinc for another 60 min. For synthesis of lipid II ending D-Ala-D-Ser the UDP-MurNAc-pentapeptide (Ala-Glu-Lys-Ala-Ser) was used. The wall teichoic acid precursor lipid III (undecaprenyl-PP-GlcNAc) was prepared using purified TarO enzyme⁴⁴. In short, purified recombinant TarO protein was incubated in the presence of 250 nmol C₅₅-P, 2.5 mmol of UDP-GlcNAc in 83 mM Tris-HCl (pH 8.0), 6.7 mM MgCl₂, 8.3% (v/v) dimethyl sulfoxide, and 10 mM *N*-lauroylsarcosine. The reaction was initiated by the addition of 150 µg of TarO-His₆ and incubated for 3 h at 30 °C. Lipid intermediates were extracted from the reaction mixtures with *n*-butanol/pyridine acetate (pH 4.2) (2:1; vol/vol), analysed by TLC and purified. C₅₅-P and C₅₅-PP were purchased from Larodan Fine Chemicals, Sweden. [¹⁴C]-C₅₅-PP was synthesized using purified *S. aureus* UppS enzyme based on a protocol elaborated for *E. coli* undecaprenyl pyrophosphate synthase⁴⁷. Synthesis was performed using 0.5 nmol [¹⁴C]-farnesyl pyrophosphate (ARC; 2.035 GBq mmol⁻¹), 5 nmol isopentenyl pyrophosphate (Sigma-Aldrich) and 5 µg UppS enzyme in 100 mM HEPES, pH 7.6, 50 mM KCl, 5 mM MgCl₂, and 0.1% Triton X-100. After 3 h of incubation at 30 °C radiolabelled C₅₅-PP was extracted from the reaction mixture with BuOH and dried

under vacuum. Product identity was confirmed by TLC analysis. Experiments were performed with biological replicates.

Antagonization assays.

Antagonization of the antibiotic activity of teixobactin by potential target molecules was performed by an MIC-based setup in microtitre plates. Teixobactin ($8\times$ MIC) was mixed with potential HPLC-purified antagonists (C_{55} -P, farnesyl-PP [C_{15} -PP; Sigma Aldrich], C_{55} -PP, UDP-MurNAc-pentapeptide, UDP-GlcNAc [Sigma Aldrich], lipid I, lipid II, and lipid III) at a fixed molar ratio (fivefold molar excess) or at increasing concentrations with respect to the antibiotic, and the lowest ratio leading to complete antagonization of teixobactin activity was determined. *S. aureus* ATCC 29213 (5×10^5 c.f.u. per ml) were added and samples were examined for visible bacterial growth after overnight incubation. Vancomycin ($8\times$ MIC) was used as a control. Experiments were performed with biological replicates.

Complex formation of teixobactin.

Binding of teixobactin to C_{55} -P, C_{55} -PP, lipid I, lipid II, lipid II-D-Ala-D-Ser, lipid II-D-Ala-D-Lac and lipid III was analysed by incubating 2 nmol of each purified precursor with 2 to 4 nmoles of teixobactin in 50 mM Tris/HCl, pH 7.5, for 30 min at room temperature. Complex formation was analysed by extracting unbound precursors from the reaction mixture with n-butanol/pyridine acetate (pH 4.2) (2:1; vol/vol) followed by TLC analysis using chloroform/methanol/water/ammonia (88:48:10:1, v/v/v/v) as the solvent and detection of lipid-containing precursors by phosphomolybdic acid staining⁴⁸. Experiments were performed with biological replicates.

hERG inhibition testing.

Teixobactin was tested for inhibition of hERG activity using an IonWorksTM HT instrument (Molecular Devices Corporation), which performs electrophysiology measurements in a 384-well plate (PatchPlate). Chinese hamster ovary (CHO) cells stably transfected with hERG (cell-line obtained from Cytomyx, UK) were prepared as a single-cell suspension in extracellular solution (Dulbecco's phosphate buffered saline with calcium and magnesium pH 7), and aliquots added to each well of the plate. The cells were positioned over a small hole at the bottom of each well by applying a vacuum beneath the plate to form an electrical seal. The resistance of each seal was measured via a common ground-electrode in the intracellular compartment and individual electrodes placed into each of the upper wells. Experiments were performed with three biological replicates.

Cytochrome P450 inhibition.

Teixobactin and control compounds were incubated with human liver microsomes at 37 °C to determine their effect on five major human cytochromes P450s (CYP). The assay included probe substrates (midazolam for Cyp3A4, testosterone for Cyp3A4, tolbutamide for Cyp2C9, dextro-methorphan for Cyp2D6, S-mephenytoin for Cyp2C19, and phenacetin for Cyp1A2, 2 mM NADPH, 3 mM $MgCl_2$ in 50 mM potassium phosphate buffer, pH 7.4. The final microsomal concentration was 0.5 mg ml⁻¹. NADPH was added last to start the assay. After ten minutes of incubation, the amount of probe metabolite in the supernatant was

determined by LC/MS/MS using an Agilent 6410 mass spectrometer coupled with an Agilent 1200 HPLC and a CTC PAL chilled autosampler, all controlled by MassHunter software (Agilent). Experiments were performed with three biological replicates.

***In vitro* genotoxicity.**

Teixobactin was tested in an *in vitro* micronucleus test that employs fluorescent cell imaging to assess cytotoxicity and quantify micronuclei. The assay was performed with CHO-K1 cells in the presence or absence of Aroclor (to induce CYP activity)-treated rat liver S9 fraction (contains phase I and phase II metabolizing enzymes) to determine if any genotoxic metabolites are produced. No evidence of genotoxicity was observed with teixobactin up to 125 $\mu\text{g ml}^{-1}$ (the highest concentration tested) under either condition. Experiments were performed with three biological replicates.

DNA binding.

Compounds were serially diluted and mixed with sheared salmon sperm DNA (6.6 mg ml^{-1} final concentration). An aliquot was spotted onto a lawn of growing *S. aureus* NCTC 8325–4 cells, and the zones of growth inhibition measured after 20 h of growth at 37 °C. A reduction in the inhibition zone size in the presence of DNA would indicate loss of antibacterial activity due to binding to the DNA. Experiments were performed with three biological replicates.

Plasma protein binding.

Protein binding of teixobactin in rat plasma was determined using a Rapid Equilibrium Dialysis (RED) kit (Pierce) with LC–MS/MS analysis. Teixobactin (10 $\mu\text{g ml}^{-1}$) and rat plasma in 5% dextrose containing 0.005% polysorbate 80 were added to one side of the single-use RED plate dialysis chamber having an 8kD MW cutoff membrane. Following four hours of dialysis the samples from both sides were processed and analysed by LC/MS/MS. The teixobactin concentration was determined, and the percentage of compound bound to protein was calculated. Teixobactin exhibited 84% plasma protein binding. Experiments were performed with three biological replicates.

Microsomal stability.

The metabolic stability of teixobactin was measured in rat liver microsomes (Invitrogen/Life Technologies, CA) using NADPH Regeneration System (Promega) by monitoring the disappearance of the compound over an incubation period of two hours. Teixobactin (60 $\mu\text{g ml}^{-1}$) or verapamil (5 μM) serving as positive control were added to 1 mg ml^{-1} microsomes at 37 °C. Aliquots were removed at 0 h, 0.5 h, 1 h and 2 h, and the reactions stopped by addition of 3 volumes of ice-cold acetonitrile. Samples were analysed by LC/MS/MS. Experiments were performed with three biological replicates.

Animal studies.

All animal studies were carried out at Vivisource Laboratories, (Waltham, MA), and University of North Texas Health Science Center (Houston, TX), and conformed to institutional animal care and use policies. Neither randomization nor blinding was deemed

necessary for the animal infection models, and all animals were used. All animal studies were performed with female CD-1 mice, 6–8-weeks old.

Pharmacokinetic analysis.

CD-1 female mice were injected intravenously with a single dose of 20 mg per kg in water and showed no adverse effects. Plasma samples were taken from 3 mice per time point (5, 15, 30 min; 1, 2, 4, 8 and 24 h post-dose). An aliquot of plasma sample or calibration sample was mixed with three volumes of methanol containing internal standard, incubated on ice for 5 min, and centrifuged. The protein-free supernatant was analysed by LC/MS/MS using an Agilent 6410 mass spectrometer coupled with an Agilent 1200 HPLC and a CTC PAL chilled autosampler, all controlled by MassHunter software (Agilent). After separation on a C18 reverse phase HPLC column (Agilent) using an acetonitrile-water gradient system, peaks were analysed by mass spectrometry using ESI ionization in MRM mode. The product m/z analysed was 134.1D, which provided a low limit of quantification of 1 ng ml⁻¹. The mean plasma concentration and the standard deviation from all 3 animals within each time point were calculated. PK parameters of test agent were calculated with a non-compartmental analysis model based on WinNonlin. The mean plasma concentrations from all 3 mice at each time point were used in the calculation.

Mouse sepsis protection model.

Teixobactin was tested against clinical isolate *S. aureus* MRSA ATCC33591 in a mouse septicemia protection assay to assess its *in vivo* bioavailability and PD₅₀ (protective dose resulting in 50% survival of infected mice after 48 h). CD-1 female mice were infected with 0.5 ml of bacterial suspension (3.28×10^7 c.f.u. per mouse) via intraperitoneal injection, a concentration that achieves at least 90% mortality within 48 h after infection. At one hour post-infection, mice (6 per group) were treated with teixobactin at single intravenous doses of 20, 10, 5, 2.5, and 1 mg per kg. Infection control mice were dosed with vehicle or vancomycin. Survival is observed 48 h after infection and the probability determined by non-parametric log-rank test. To obtain the PD₅₀, the experiment was repeated at lower doses 5, 1, 0.5, 0.25, and 0.1 mg per kg.


Mouse thigh infection model.

Teixobactin was tested against MRSA ATCC33591 in a neutropenic mouse thigh infection model. Female CD-1 mice were rendered neutropenic by cyclophosphamide (two consecutive doses of 150 and 100 mg per kg delivered on 4 and 1 days before infection). Bacteria were resuspended in sterile saline, adjusted to an A_{625nm} (OD₆₂₅) of 0.1, and a 0.1 ml inoculum (2.8×10^5 c.f.u. per mouse) injected into the right thighs of mice. At 2 h post-infection, mice received treatment with teixobactin at 1, 2.5, 5, 10 or 20 mg per kg administered in a single dose, intravenous injection (four mice per group). One group of infected mice was euthanized and thighs processed for c.f.u. to serve as the time of treatment controls. At 26 h post-infection mice were euthanized by CO₂ inhalation. The right thighs were aseptically removed, weighed, homogenized, serially diluted, and plated on trypticase soy agar for c.f.u. titres.

Mouse lung infection model.


Teixobactin was tested against *Streptococcus pneumoniae* ATCC 6301 (UNT012–2) in an immunocompetent mouse pneumonia model to determine the compound's potential to treat acute respiratory infections. CD-1 mice were infected intranasally (1.5×10^6 c.f.u. per mouse). The compound was delivered intravenously at 24 and 36 h post-infection, whereas amoxicillin was delivered subcutaneously at a single concentration to serve as positive control. Teixobactin was delivered at doses ranging from 0.5 to 10 mg per kg per dose (5 mice per dose). At 48 h post-infection, treated mice were euthanized, lungs aseptically removed and processed for c.f.u. counts.

Extended Data



Extended Data Figure 1 |. The iChip.

a–c, The iChip (**a**) consists of a central plate (**b**) which houses growing microorganisms, semi-permeable membranes on each side of the plate, which separate the plate from the environment, and two supporting side panels (**c**). The central plate and side panels have multiple matching through-holes. When the central plate is dipped into suspension of cells in molten agar, the through-holes capture small volumes of this suspension, which solidify in the form of small agar plugs. Alternatively, molten agar can be dispensed into the chambers. The membranes are attached and the iChip is then placed in soil from which the sample originated.



Extended Data Figure 2 | 16S rRNA gene phylogeny of *Eleftheria terrae*.

a, The phylogenetic position of *E. terrae* within the class β-proteobacteria. The 16S rRNA gene sequences were downloaded from Entrez at NCBI using accession numbers retrieved from peer-reviewed publications. **b**, The phylogenetic position of *E. terrae* among its closest known relatives. The sequences were downloaded from NCBI using accession numbers retrieved from the RDP Classifier Database. For both trees, multiple sequence alignments (MSA) were constructed using ClustalW2, implementing a default Cost Matrix, the Neighbour-Joining (NJ) clustering algorithm, as well as optimized gap penalties. Resulting alignments were manually curated and phylogenetic trees were constructed leveraging PhyML 3.0 with a TN93 substitution model and 500 Bootstrap iterations of branch support. Topology search optimization was conducted using the Subtree-Pruning-Regrafting (SPR)


algorithm with an estimated Transition–Transversion ratio and gamma distribution parameters as well as fixed proportions of invariable sites.

a


Teixobactin (DMSO- <i>d</i> ₆)					
Position	δ_c	δ_H (mult., J in Hz)	Position	δ_c	δ_H (mult., J in Hz)
1	31.9	2.5 (3H, br s)	29	57.3	4.29 (1H, m)
2	61.9	4.21 (1H, dd, 9.4, 5.3)	29-NH		7.76 (1H, d, 8.8)
2-NH ^d		(2H, 9.3, 9.0, v br s)	30	36.9	1.83 (1H, m)
3	36.4	3.00 (1H, dd, 13.2, 9.4)	31	15.4 ^b	0.84 (3H, m)
		3.15 (1H, 13.2, 5.3)	32	25.3	1.11 (1H, m)
4	135.0				1.42 (1H, m)
5,5'	129.7	7.24 (2H, m)	33	11.2 ^c	0.85 (3H, m)
6,6'	128.9	7.31 (2H, m)	34	171.6 ^d	
7	127.5	7.27 (1H, m)	35	56.5	4.47 (1H, dt, 5.0, 5.2)
8	167.1		35-NH		8.37 (1H, d, 5.2)
9	57.9	4.12 (1H, dd, 7.8, 7.2)	36	62.7	3.64 (1H, m)
9-NH		8.43 (1H, d, 7.2)			3.80 (1H, dd, 10.8, 5.0)
10	36.5	1.56 (1H, m)	36-OH		exchanged
11	15.5	0.62 (1H, d, 6.7)	37	171.7 ^a	
12	24.4	0.76 (1H, m)	38	56.2	4.64 (1H, dt, 9.5, 2.2)
		1.07 (1H, m)	39	71.2	5.36 (1H, dq, 2.2, 6.4)
13	11.3	0.66 (3H, t, 7.1)	40	15.9	1.13 (3H, d, 6.4)
14	170.6		41	166.9	
15	55.6	4.34 (1H, m)	42	52.2	3.97 (1H, dq, 5.1, 7.5)
15-NH		7.88 (1H, d, 7.9)	42-NH		8.05 (1H, d, 5.1)
16	62.4	3.57 (1H, dd, 10.8, 5.6)	43	17.1	1.34 (3H, d, 7.5)
		3.63 (1H, dd, m)	44	173.1	
16-OH		exchanged	45	52.2	4.38 (1H, m)
17	170.2		45-NH		8.32 (1H, d, 9.1)
18	52.7	4.33 (1H, m)	46	37.2	2.03 (2H, m)
18-NH		7.85 (1H, d, 7.9)	47	53.5	3.90 (1H, m)
19	31.9	2.10 (2H, m)	47-NH		7.95 (1H, br s)
20	28.4	1.74 (1H, m)	48	48.3	3.36 (1H, dd, 9.4, 7.7)
		1.92 (1H, m)			3.66 (1H, t, 9.4)
21	174.4		48-NH		8.1 (1H, br s)
21-NH ₂		6.63 (1H, br s)	49	160.0	
		7.11 (1H, br s)	49-NH ^d		7.76 (2H, br s)
22	170.9 ^b		50	171.8 ^d	
23	56.8	4.36 (1H, m)	51	57.8	4.03 (1H, t, 9.4)
23-NH		7.70 (1H, d, 8.8)	51-NH		8.01 (1H, d, 9.4)
24	37.4	1.8 (2H, m)	52	36.3	1.77 (1H, m)
25	14.7 ^a	0.82 (3H, m)	53	16.0 ^b	0.81 (3H, m)
26	26.2	1.09 (1H, m)	54	24.5	0.77 (1H, m)
		1.32 (1H, m)			1.07 (1H, m)
27	10.6 ^c	0.82 (3H, m)	55	11.8 ^c	0.82 (3H, m)
28	171.4 ^a		56	169.3	

^a Assignments may be switched due to overlap.^b Assignments may be switched due to overlap.^c Assignments may be switched due to overlap.^d Appears as an ammonium salt.

b


**Extended Data Figure 3 |. NMR assignment of teixobactin.**

a, ¹³C-NMR of teixobactin (125 MHz, δ in p.p.m.). **b**, Structure of teixobactin with the NMR assignments.




Extended Data Figure 4 |. NMR spectra of teixobactin.

a, ^{13}C NMR spectrum of teixobactin. **b,** ^1H NMR spectrum. **c,** HMBC NMR spectrum. **d,** HSQC NMR spectrum. **e,** COSY NMR spectrum.




Extended Data Figure 5 |. Hypothetical biosynthesis pathway of teixobactin.

The eleven modules of the non-ribosomal peptide synthetases Txo1 and Txo2 are depicted with the growing chain attached. Each module is responsible for the incorporation of one specific amino acid in the nascent peptide chain. The *N*-methylation of the first amino acid phenylalanine is catalysed by the methyltransferase domain in module 1. The ring closure (marked by a dashed arrow) between the last isoleucine and threonine is catalysed by the thioesterase domains during molecule off-loading, resulting in teixobactin.



Extended Data Figure 6 |. Teixobactin activity against vancomycin-resistant strains.


a, Vancomycin intermediate *S. aureus* (VISA) were grown to late exponential phase and challenged with vancomycin or teixobactin. Cell numbers were determined by plating for colony counts. Data are representative of 3 independent experiments \pm s.d. **b**, Complex formation of teixobactin with cell wall precursor variants as formed by vancomycin-resistant strains. Purified lipid intermediates with altered stem peptides were incubated with teixobactin at a molar ratio of 2:1 (TEIX:lipid II variant). Reaction mixtures were extracted with BuOH/PyrAc and binding of teixobactin to lipid II variants is indicated by its absence on the thin-layer chromatogram. Migration behaviour of unmodified lipid II is used for comparison. The figure is representative of 3 independent experiments.



Extended Data Figure 7 |. Model for the mechanism of action of teixobactin.

Inhibition of cell wall synthesis by teixobactin. Lipid II, precursor of peptidoglycan, is synthesized in the cytoplasm and flipped to the surface of the inner membrane by MurJ⁴⁸ or FtsW⁴⁹. Lipid III, a precursor of wall teichoic acid (WTA), is similarly formed inside the cell and WTA lipid-bound precursors are translocated across the cytoplasmic membrane by the ABC-transporter TarGH⁵⁰. Teixobactin (TEIX) forms a stoichiometric complex with cell wall precursors, lipid II and lipid III. Abduction of these building blocks simultaneously interrupts peptidoglycan (right), WTA (left) biosynthesis as well as precursor recycling. Binding to multiple targets within the cell wall pathways obstructs the formation of a functional cell envelope. Left panel, teixobactin targeting and resistance. The producer of teixobactin is a Gram-negative bacterium which is protected from this compound by exporting it outside of its outer membrane permeability barrier. The target Gram-positive organisms do not have an outer membrane. CM, cytoplasmic membrane; CW, cell wall; OM, outer membrane; LTA, lipoteichoic acid; WTA, wall teichoic acid.

a



b

PK parameter	Definition	Value
C0 (µg/mL)	Initial concentration	27.2
AUC to Last (µg-hr/mL)	Area Under Curve to last time point	57.8
t _{1/2} (hr)	Half life	4.7
Total CL (mL/hr)	Clearance	6.9
Total CL (mL/min/kg)	Clearance	5.8
V (mL)	Volume of Distribution	47
V _{ss} (mL)	Volume of Distribution at steady state	9.7
MRT _{INF} (hr)	Mean residence time	1.4
Last Time point (hr)	–	24

Extended Data Figure 8 |. Pharmacokinetic analysis of teixobactin.

a, The mean plasma concentrations of teixobactin after a single i.v. injection of 20 mg per kg teixobactin (3 mice per time point). Data are the mean of plasma concentration, and error bars represent the standard deviation from 3 animals in each time point. **b**, Pharmacokinetic parameters of teixobactin calculated with a non-compartmental analysis model based on WinNonlin.

Extended Data Table 1 |

Antibacterial spectrum of teixobactin

	Organism	MIC (µg/mL)	Organism	MIC (µg/mL)
a	<i>Staphylococcus aureus</i>		<i>Streptococcus pneumoniae</i>	
	ATCC29213 (MSSA)	0.16–0.31	ATCC BAA 255	0.05
	NCTC8325 (MSSA)	0.08–0.31	VL-172	0.15
	ATCC 33591 (MRSA)	0.16–0.31	VL-190	0.15
	NRS54(MRSA)	0.078–0.16	ATCC 10813	0.08
	NRS108 (MRSA, also synergic ^R)	0.16	ATCC 6303	0.02–0.04
	NRS269 (MRSA, also tigecycline ^R)	0.16–0.31	BAA 1407	0.04
	ATCC 700699 (GISA)	0.31	<i>Bacillus anthracis</i>	
	<i>S. epidermidis</i>		Sterne	0.02
	ATCC35984=NRS101 (<i>mecA</i> positive)	0.078–0.16	<i>B. anthracis</i> BB Resources ^a Isolates	
	NRS8 (<i>mecA</i> positive)	0.16–0.31	NR-36 NRS 1008	0.06
	NRS34 (<i>mecA</i> positive)	0.16	NR-38 Pasteur Vaccine No.1	0.06
	<i>S. haemolyticus</i>		NR-41 Graves	0.06
	NRS9 (<i>mecA</i> positive)	0.08	NR-46 46-PY-5	0.06
	NRS69 (<i>mecA</i> positive)	0.15	NR-411 Ames, A0462	0.06
	<i>Enterococcus</i>		NR-412 Kruger B	0.06–0.125
	<i>E. faecium</i> BM4147 (<i>aac</i> (6′)- <i>le-aph</i> (2′′), <i>van</i> ^R)	0.31	NR-413 CNR/A	0.125
	<i>E. faecium</i> E4sol (<i>vancomycin</i> ^S)	0.31	NR-414 Vollum	0.06
	<i>E. faecalis</i> ATCC51575 (<i>vancomycin</i> ^R)	0.31–0.63	NR-415 WNA	0.06
	<i>E. faecalis</i> M192 (<i>vancomycin</i> ^S)	0.63	NR-3838 Ames	0.06
	<i>Mycobacterium</i>		Other Gram-positive	
	<i>Mycobacterium smegmatis</i> me ² 155	0.31	<i>Streptococcus pyogenes</i> ATCC19615	0.31
	<i>M. tuberculosis</i> H37Rv	0.125	<i>S. warneri</i> NRS138	0.02
	<i>M. tuberculosis</i> (clinical isolate 70)	0.125	<i>Bacillus subtilis</i> 1A1	0.02
	<i>M. tuberculosis</i> (clinical isolate 76)	0.125–0.25	<i>Clostridium difficile</i> CD196	0.005
	<i>M. tuberculosis</i> (clinical isolate 82)	0.125–0.25	<i>Propionibacterium acnes</i> ATCC6919	0.078
	<i>M. tuberculosis</i> (clinical isolate 102)	0.25		
	Gram-negative			
	<i>Haemophilus influenzae</i> SJ7	2.5	<i>E. coli</i> K12	25
	<i>Klebsiella pneumoniae</i> ATCC 700603	20	<i>E. coli</i> WD153 (AB1157; <i>asmB1</i> <i>MolCv.kan</i>)	2.5
	<i>Pseudomonas aeruginosa</i> PA-01	>100	<i>E. coli</i> WD159 (AB1157; <i>asmB1</i> & <i>rfaC</i> : <i>kan</i>)	2.5
	<i>Klebsiella pneumoniae</i> ATCC 43816	>40	<i>E. coli</i> ATCC 25922	25

	Organism	MIC (μg/mL)	Organism	MIC (μg/mL)
	<i>Yersinia pestis</i> KIM 100 deletion <i>pDC1</i>	50–100	<i>E. coli</i> mutS	25
	<i>Neisseria gonorrhoeae</i>	25	<i>Bacteriodes fragilis</i> ATCC 25825	200

b	Organism	# Isolates	Drug	MIC Range (μg/mL)	MIC ₉₀ (μg/mL)	Organism	# Isolates	Drug	MIC Range (μg/mL)	MIC ₉₀ (μg/mL)
	<i>Staphylococcus aureus</i> MSSA	20	Teixobactin	0.06–0.25	0.25	<i>Enterococcus faecalis</i> 50% VRE	10	Teixobactin	0.5–1	0.5
			Linezolid	2–4	4			Linezolid	1–2	2
			Vancomycin	0.5–1	1			Vancomycin	0.5–>32	>32
			Daptomycin	0.12–0.25	0.25			Daptomycin	0.12–8	0.5
	<i>S. aureus</i> MRSA	20	Teixobactin	0.06–0.5	0.25	<i>E. faecium</i> 50% VRE	10	Teixobactin	0.25–1	1
			Linezolid	2–4	4			Linezolid	1–2	2
			Vancomycin	0.5–2	1			Vancomycin	0.5–>32	>32
			Daptomycin	0.12–0.25	0.25			Daptomycin	0.5–1	1
	<i>S. aureus</i> VISA	10	Teixobactin	0.12–1	0.5	<i>Streptococcus pneumoniae</i> 28.6% PSSP, 33.3% RSP, 38.1% PRSP	20	Teixobactin	0.03–0.06	0.03
			Linezolid	1–4	2			Linezolid	0.25–1	1
			Vancomycin	1–8	8			Vancomycin	0.12–0.5	0.25
			Daptomycin	0.25–1	1			Daptomycin	<0.03–0.06	0.03
	<i>S. aureus</i> Daptomycin ^{NS}	5	Teixobactin	0.12–0.5	-	<i>S. pyogenes</i>	10	Teixobactin	0.03–0.06	0.06
			Linezolid	1–32	-			Linezolid	0.5–1	1
			Vancomycin	0.5–8	-			Vancomycin	0.25	0.25
			Daptomycin	2–8	-			Daptomycin	0.03–0.06	0.06
	<i>S. aureus</i> Linezolid ^R	5	Teixobactin	0.12–0.5	-	<i>S. agalactiae</i>	10	Teixobactin	0.06–0.12	0.12
			Linezolid	16–>32	-			Linezolid	0.5–2	1
			Vancomycin	1	-			Vancomycin	0.25–0.5	0.5
			Daptomycin	0.25–0.5	-			Daptomycin	0.06–0.25	0.12
	<i>S. epidermidis</i>	20	Teixobactin	0.03–0.25	0.12	Viridans Group Streptococci ^I	5	Teixobactin	0.03–0.12	-
			Linezolid	1–8	2			Linezolid	0.5–1	-
			Vancomycin	1–2	2			Vancomycin	0.25–0.5	-
			Daptomycin	0.06–0.25	0.25			Daptomycin	0.06–0.25	-

^a, Antibacterial spectrum of teixobactin. MIC was determined by broth microdilution.

^a *B. anthracis* BB resources isolates are from NIH Biodefense and Emerging Infections Research Resources repository.

^b, Antibacterial activity of teixobactin and known drugs against contemporary clinical isolates.

^l In the Viridans Group Streptococci, one isolate of each of the following was tested *S. sanguis*, *S. mitis*, *S. anginosus*, *S. intermedius* and *S. salivarius*. PISP, penicillin-intermediate *S. pneumoniae*, PRSP, penicillin-resistant *S. pneumoniae*, PSSP, penicillin-sensitive *S. pneumoniae*.

Extended Data Table 2 |

Antagonization of the antimicrobial activity of teixobactin by cell wall precursors

a

antagonist	C ₅₅ -PP	C ₅₅ -PP	C ₅₅ -PP	lipid I	lipid II	lipid III	UDP-MurNAc-pentapeptide	UDP-GlcNAc
teixobactin	–	+	+	+		+	–	–
vancomycin	–	–	nd	+	+	–	nd	nd

(+) antibiotic activity antagonized, (–) antibiotic activity unaffected, (nd) not determined

b

lipid intermediate	molar ratio of precursor to teixobactin						
	Ox	0.5 x	1 X	2.5 x	5 x	7.5 x	10 x
lipid II	–	+	+	+	+	+	+
C ₅₅ -PP	–	–	–	–	+	+	+

^{dr} *S. aureus* ATCC 29213 was incubated with teixobactin and vancomycin at 8 × MIC in nutrient broth in a microtitre plate, and growth was measured after a 24 h incubation at 37 °C. Putative HPLC-purified antagonists (undecaprenyl-phosphate [C₅₅-P], farnesyl-pyrophosphate [C₁₅-PP], undecaprenyl-pyrophosphate [C₅₅-PP], UDP-MurNAc-pentapeptide, UDP-GlcNAc, lipid I, lipid II, and lipid III) were added in a fivefold molar excess with respect to the antibiotic. **b**, Teixobactin at 8 × MIC was exposed to increasing concentrations of putative antagonistic lipid intermediates. Experiments were performed with biological replicates.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by NIH grant T-RO1 AI085585 to K.L., by NIH grant AI085612 to A.L.S., by the Charles A. King Trust to B.P.C., and by the German Research Foundation (DFG; SCHN1284/1-2) and the German Center for Infection Research (DZIF) to T.S. and I.E. The NRS strains were provided by the Network on Antimicrobial Resistance in *Staphylococcus aureus* for distribution by BEI Resources, NIAID, NIH. Preclinical Services offered by NIAID are gratefully acknowledged. We thank H. G. Sahl for reading the manuscript and making comments, A. Makriyannis for suggestions, P. Muller, B. Berdy and S. Kaluziak for taxonomy analysis, and M.Josten for performing mass spectrometry analysis.

References

1. Fleming A On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *Br. J. Exp. Pathol* 10, 226–236 (1929).
2. Kardos N & Demain AL Penicillin: the medicine with the greatest impact on therapeutic outcomes. *Appl. Microbiol. Biotechnol* 92, 677–687 (2011). [PubMed: 21964640]
3. Schatz A, Bugie E & Waksman SA Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. *Proc. Soc. Exp. Biol. Med* 55, 66–69 (1944).
4. Spellberg B & Shlaes D Prioritized current unmet needs for antibacterial therapies. *Clin. Pharmacol. Ther* 96, 151–153 (2014). [PubMed: 25056396]

5. Bush K et al. Tackling antibiotic resistance. *Nature Rev. Microbiol* 9, 894–896 (2011). [PubMed: 22048738]
6. Payne DJ, Gwynn MN, Holmes DJ & Pompliano DL Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nature Rev. Drug Discov* 6, 29–40 (2007). [PubMed: 17159923]
7. Lewis K Antibiotics: Recover the lost art of drug discovery. *Nature* 485, 439–440 (2012). [PubMed: 22622552]
8. Lewis K Platforms for antibiotic discovery. *Nature Rev. Drug Discov* 12, 371–387 (2013). [PubMed: 23629505]
9. Kaerberlein T, Lewis K & Epstein SS Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. *Science* 296, 1127–1129 (2002). [PubMed: 12004133]
10. Nichols D et al. Use of ichip for high-throughput *in situ* cultivation of “uncultivable” microbial species. *Appl. Environ. Microbiol* 76, 2445–2450 (2010). [PubMed: 20173072]
11. D’Onofrio A et al. Siderophores from neighboring organisms promote the growth of uncultured bacteria. *Chem. Biol* 17, 254–264 (2010). [PubMed: 20338517]
12. Gavrish E et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills *Mycobacterium tuberculosis* by targeting the ATP-dependent protease ClpC1P1P2. *Chem. Biol* 21, 509–518 (2014). [PubMed: 24684906]
13. Wilson MC et al. An environmental bacterial taxon with a large and distinct metabolic repertoire. *Nature* 506, 58–62 (2014). [PubMed: 24476823]
14. Nichols D et al. Short peptide induces an “uncultivable” microorganism to grow *in vitro*. *Appl. Environ. Microbiol* 74, 4889–4897 (2008). [PubMed: 18515474]
15. Sakoulas G et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *J. Clin. Microbiol* 42, 2398–2402 (2004). [PubMed: 15184410]
16. Kollef MH Limitations of vancomycin in the management of resistant staphylococcal infections. *Clin. Infect. Dis* 45 (Suppl 3), S191–S195 (2007). [PubMed: 17712746]
17. Arthur M, Depardieu F, Reynolds P & Courvalin P Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. *Mol. Microbiol* 21, 33–44 (1996). [PubMed: 8843432]
18. Bugg TD et al. Molecular basis for vancomycin resistance in *Enterococcus faecium* BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. *Biochemistry* 30, 10408–10415 (1991). [PubMed: 1931965]
19. Marshall CG, Broadhead G, Leskiw BK & Wright GD D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. *Proc. Natl Acad. Sci. USA* 94, 6480–6483 (1997). [PubMed: 9177243]
20. D’Elia MA et al. Lesions in teichoic acid biosynthesis in *Staphylococcus aureus* lead to a lethal gain of function in the otherwise dispensable pathway. *J. Bacteriol* 188, 4183–4189 (2006). [PubMed: 16740924]
21. Bierbaum G & Sahl HG Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. *Arch. Microbiol* 141, 249–254 (1985). [PubMed: 4004448]
22. O’Riordan K & Lee JC *Staphylococcus aureus* capsular polysaccharides. *Clin. Microbiol. Rev* 17, 218–234 (2004). [PubMed: 14726462]
23. Xayarath B & Yother J Mutations blocking side chain assembly, polymerization, or transport of a Wzy-dependent *Streptococcus pneumoniae* capsule are lethal in the absence of suppressor mutations and can affect polymer transfer to the cell wall. *J. Bacteriol* 189, 3369–3381 (2007). [PubMed: 17322316]
24. Degen D et al. Transcription inhibition by the depsipeptide antibiotic salinamide A. *eLife* 3, e02451 (2014). [PubMed: 24843001]
25. Doroghazi JR et al. A roadmap for natural product discovery based on large-scale genomics and metabolomics. *Nature Chem. Biol* 10, 963–968 (2014). [PubMed: 25262415]
26. Forsberg KJ et al. Bacterial phylogeny structures soil resistomes across habitats. *Nature* 509, 612–616 (2014). [PubMed: 24847883]

27. Conlon BP et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. *Nature* 503, 365–370 (2013). [PubMed: 24226776]
28. Schneider T & Sahl HG An oldie but a goodie—cell wall biosynthesis as antibiotic target pathway. *Int. J. Med. Microbiol* 300, 161–169 (2010). [PubMed: 20005776]
29. Leclercq R, Derlot E, Duval J & Courvalin P Plasmid-mediated resistance to vancomycin and teicoplanin in *Enterococcus faecium*. *N. Engl. J. Med* 319, 157–161 (1988). [PubMed: 2968517]
30. Wiedemann I et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J. Biol. Chem* 276, 1772–1779 (2001). [PubMed: 11038353]
31. Hasper HE et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. *Science* 313, 1636–1637 (2006). [PubMed: 16973881]
32. Schneider T et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. *Science* 328, 1168–1172 (2010). [PubMed: 20508130]
33. Baker GC, Smith JJ & Cowan DA Review and re-analysis of domain-specific 16S primers. *J. Microbiol. Methods* 55, 541–555 (2003). [PubMed: 14607398]
34. Aziz RK et al. The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* 9, 75 (2008). [PubMed: 18261238]
35. Auch AF, Klenk HP & Goker M Standard operating procedure for calculating genome-to-genome distances based on high-scoring segment pairs. *Stand. Genomic Sci* 2, 142–148 (2010). [PubMed: 21304686]
36. Auch AF, von Jan M, Klenk HP & Goker M Digital DNA–DNA hybridization for microbial species delineation by means of genome-to-genome sequence comparison. *Stand. Genomic Sci* 2, 117–134 (2010). [PubMed: 21304684]
37. Meier-Kolthoff JP, Auch AF, Klenk HP & Goker M Genome sequence-based species delimitation with confidence intervals and improved distance functions. *BMC Bioinformatics* 14, 60 (2013). [PubMed: 23432962]
38. Röttig M et al. NRPSpredictor2—a web server for predicting NRPS adenylation domain specificity. *Nucleic Acids Res.* 39, W362–W367 (2011). [PubMed: 21558170]
39. Arhin FF et al. Effect of polysorbate 80 onoritavancin binding to plastic surfaces: implications for susceptibility testing. *Antimicrob. Agents Chemother* 52, 1597–1603 (2008). [PubMed: 18299406]
40. Bogdanovich T, Ednie LM, Shapiro S & Appelbaum PC Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. *Antimicrob. Agents Chemother* 49, 4210–4219 (2005). [PubMed: 16189100]
41. Metzler K, Drlica K & Blondeau JM Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of *Streptococcus pneumoniae*. *J. Antimicrob. Chemother* 68, 631–635 (2013). [PubMed: 23169894]
42. Schneider T et al. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. *Antimicrob. Agents Chemother* 53, 1610–1618 (2009). [PubMed: 19164139]
43. Brötz H, Bierbaum G, Reynolds PE & Sahl HG The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. *Eur. J. Biochem* 246, 193–199 (1997). [PubMed: 9210483]
44. Müller A, Ulm H, Reder-Christ K, Sahl HG & Schneider T Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors. *Microb. Drug Resist* 18, 261–270 (2012). [PubMed: 22432708]
45. Schneider T et al. In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of *Staphylococcus aureus*. *Mol. Microbiol* 53, 675–685 (2004). [PubMed: 15228543]
46. El Ghachi M, Derbise A, Bouhss A & Mengin-Lecreulx D Identification of multiple genes encoding membrane proteins with undecaprenyl pyrophosphate phosphatase (UppP) activity in *Escherichia coli*. *J. Biol. Chem* 280, 18689–18695 (2005). [PubMed: 15778224]
47. El Ghachi M, Bouhss A, Blanot D & Mengin-Lecreulx D The *bacA* gene of *Escherichia coli* encodes an undecaprenyl pyrophosphate phosphatase activity. *J. Biol. Chem* 279, 30106–30113 (2004). [PubMed: 15138271]

48. Sham LT et al. Bacterial cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. *Science* 345, 220–222 (2014). [PubMed: 25013077]
49. Mohammadi T et al. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. *EMBO J.* 30, 1425–1432 (2011). [PubMed: 21386816]
50. Lazarevic V & Karamata D The tagGH operon of *Bacillus subtilis* 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. *Mol. Microbiol* 16, 345–355 (1995). [PubMed: 7565096]




Figure 1 |. The structure of teixobactin and the predicted biosynthetic gene cluster.

a, The two NRPS genes, the catalytic domains they encode, and the amino acids incorporated by the respective modules. Domains: A, adenylation; C, condensation; MT, methylation (of phenylalanine); T, thiolation (carrier); and TE, thioesterase (Ile-Thr ring closure). NmPhe, *N*-methylated phenylalanine. **b**, Schematic structure of teixobactin. The *N*-methylation of the first phenylalanine is catalysed by the methyltransferase domain in module 1. The ring closure between the last isoleucine and threonine is catalysed by the thioesterase domains during molecule off-loading, resulting in teixobactin. **c**, Teixobactin structure.




Figure 2 | Time-dependent killing of pathogens by teixobactin.

a, b, *S. aureus* were grown to early (**a**), and late (**b**) exponential phase and challenged with antibiotics. Data are representative of 3 independent experiments \pm s.d. **c,** Teixobactin treatment resulted in lysis. The figure is representative of 3 independent experiments. **d,** Resistance acquisition during serial passaging in the presence of sub-MIC levels of antimicrobials. The y axis is the highest concentration the cells grew in during passaging. For ofloxacin, $256 \times \text{MIC}$ was the highest concentration tested. The figure is representative of 3 independent experiments.




Figure 3 |. Teixobactin binds to cell wall precursors.

a, Impact of teixobactin (TEIX) on macromolecular biosyntheses in *S. aureus*. Incorporation of 3H -thymidine (DNA), 3H -uridine (RNA), 3H -leucine (protein), and 3H -glucosamine (peptidoglycan) was determined in cells treated with teixobactin at $1 \times MIC$ (grey bars). Ciprofloxacin ($8 \times MIC$), rifampicin ($4 \times MIC$), vancomycin ($2 \times MIC$) and erythromycin ($2 \times MIC$) were used as controls (white bars). Data are means of 4 independent experiments \pm s.d. **b**, Intracellular accumulation of the cell wall precursor UDP-MurNAc-pentapeptide after treatment of *S. aureus* with teixobactin. Untreated and vancomycin (VAN)-treated ($10 \times MIC$) cells were used as controls. UDP-MurNAc-pentapeptide was identified by mass spectrometry as indicated by the peak at m/z 1,149.675. The experiment is representative of 3 independent experiments. **c**, The effect of teixobactin on precursor consuming reactions. Experiments were performed in 3 biological replicates and data are presented as mean \pm s.d. **d**, Complex formation of teixobactin with purified cell wall precursors. Binding of teixobactin is indicated by a reduction of the amount of lipid intermediates (visible on the

thin-layer chromatogram). The figure is representative of two independent experiments. **e**, A model of teixobactin targeting and resistance. The teixobactin producer is a Gram-negative bacterium protected from this compound by exporting it across the outer membrane permeability barrier (upper panel). In target Gram-positive organisms lacking an outer membrane, the targets are readily accessible on the outside where teixobactin binds precursors of peptidoglycan (PG) and WTA. CM, cytoplasmic membrane; CW, cell wall; OM, outer membrane; T, teixobactin.




Figure 4 |. Teixobactin is efficacious in three mouse models of infection.

a, Single dose treatment (i.v., 1 h post-infection, 6 mice per group) with teixobactin and vancomycin in septicemia protection model using MRSA. Survival is depicted 48 h after infection. **b**, Single dose (i.v., 2 h post-infection, 4 mice per group) treatment with teixobactin and vancomycin in neutropenic mouse thigh infection model using MRSA. For drug-treated animals, thigh colony-forming units (c.f.u.) were determined at 26 h post-infection. For controls, c.f.u. in thighs were determined at 2 h and 26 h post-infection. **c**, Two dose treatment, 5 mice per group, with teixobactin (i.v., 24 h and 36 h post-infection) and single dose treatment with amoxicillin (subcutaneous, 24 h post-infection) in immunocompetent lung infection model using *S. pneumoniae*. Lung c.f.u. were determined at 48 h post-infection. The c.f.u. from each mouse are plotted as individual points and error

bars represent the deviation within an experimental group. $*P < 0.05$, $***P < 0.001$ (determined by non-parametric log-rank test).

Table 1 |

Activity of teixobactin against pathogenic microorganisms

Organism and genotype	Teixobactin MIC($\mu\text{g ml}^{-1}$)
<i>S. aureus</i> (MSSA)	0.25
<i>S. aureus</i> + 10% serum	0.25
<i>S. aureus</i> (MRSA)	0.25
<i>Enterococcus faecalis</i> (VRE)	0.5
<i>Enterococcus faecium</i> (VRE)	0.5
<i>Streptococcus pneumoniae</i> (penicillin ^R)	0.03
<i>Streptococcus pyogenes</i>	0.06
<i>Streptococcus agalactiae</i>	0.12
Viridans group streptococci	0.12
<i>B. anthracis</i>	0.06
<i>Clostridium difficile</i>	0.005
<i>Propionibacterium acnes</i>	0.08
<i>M. tuberculosis</i> H37Rv	0.125
<i>Haemophilus influenzae</i>	4
<i>Moraxella catarrhalis</i>	2
<i>Escherichia coli</i>	25
<i>Escherichia coli</i> (asmB1)	2.5
<i>Pseudomonas aeruginosa</i>	>32
<i>Klebsiella pneumoniae</i>	>32

The MIC was determined by broth microdilution. MSSA, methicillin-sensitive *S. aureus*; VRE, vancomycin-resistant enterococci.